Cell-Based Assays: World Market Prospects 2013-2023

February 2013 | 132 pages | ID: C2903986030EN
Visiongain

Abstracts

Cell-based testing for pharma - where are that technology and its revenues heading?

Find what the future holds for cell assay technologies. Visiongain's updated report gives you revenue predictions to 2023. There you discover sales data, R&D trends, opportunities and prospects.

You find the potential of those biotechnologies. See forecasted sales at overall world market, submarket and national level. Also you assess emerging trends and predicted events. Many opportunities remain - you discover the areas to prosper.

Cellular assays form an important part of drug discovery and testing. With our report, you assess products, services, technologies (platforms) and companies in that fast-growing field.

Forecasts and other analyses show you prospects and opportunities

In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends. You receive 49 tables, 46 charts and three research interviews.

Our new study lets you investigate the most promising and lucrative aspects of cell-based systems. We help you stay ahead in knowledge. Reduce the risk of being left behind.

The following sections show how you discover the future of cell-based assaying.

Find prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for submarkets:

• Products
• Services.

You also find world-level revenue forecasts for these allied markets:

• Pharmaceutical R&D - global spending forecast to 2023
• Forecasts of biological drug submarkets in 2016.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing what's likely to achieve the most success.

Find where growth can occur. Our work also breaks the main world forecast into geographical markets.

See prospects in leading countries

Medical R&D worldwide will influence the drug testing industry, with rising demand for cell assays in developed and developing countries. There exist many opportunities.

You see individual revenue forecasts to 2023 for eleven national markets:

• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC nations).

Our analyses show revenue growth for cellular assays will occur in established and emerging national markets. Developments from 2013 will stimulate expansion of that industry and its sales.

You see trends for technological development

Our report lets you investigate established and emerging trends for cell assaying:

• Lead identification and toxicity testing
• Detection, including label-free technology
• Reporter genes
• Immortalised cell lines
• Primary cells
• Stem cells.

Our study also discusses applications of those cellular technologies:

• Target validation
• Primary screening
• Secondary screening
• ADME screening
• High throughput screening.

Discover progress. You assess innovations, hearing about progress and finding its significance.

For large companies and specialty firms there exist many opportunities. Our work explains, covering many issues.

What affects the cell assays field?

Our report discusses trends, issues and events affecting that industry, market and environment from 2013, looking ahead:

• Product categories - equipment, disposables and consumables
• Applications and cellular testing as a share of pharma R&D spending
• Strengths and weaknesses of that analytical industry and market
• Use of stem cells
• 3D cell culture - closer to the true cellular environment.

We also discuss these aspects of the field:

• G-protein-coupled receptors (GPCRs)
• Biologics (biological drugs) and biosimilars
• Miniaturisation and automation, including microfluidics
• Multiplexing - making assays more efficient
• High content screening (HCS)
• Outsourcing (off-shoring) of cell-based testing.

You explore technological, economic and political questions, assessing companies, competition and outlooks for business. See what the future holds.

Leading companies and 2016 market value

We predict the world market for cell assays will reach $4.7bn in 2016, and expand further to 2023.

From 2013, cell-based testing systems will gain rising shares of the pharma analytical market and achieve high revenues. Cellular screening of drugs holds great scope for investment, technological advances and commercial success.

You explore products, services and organisations with high potential. Our work discusses these leading companies, including contract service providers (CROs):

• Covance
• Pharmaceutical Product Development (PPD)
• Charles River Laboratories
• BD Biosciences
• GE Healthcare
• Beckman Coulter
• DiscoveRx
• EMD Millipore.

We also discuss these organisations and others:

• Evotec
• Life Technologies (Invitrogen)
• PerkinElmer
• MD Biosciences
• Sigma-Aldrich
• Thermo Fisher Scientific
• Fluofarma
• Marin Biologic Laboratories.

From 2013 to 2023 there will arise many opportunities. Our report shows you the technological and commercial possibilities, helping you stay ahead.

Seven main ways Cell-Based Assays: World Market Prospects 2013-2023 helps

In particular, then, our investigation gives you the following knowledge:

• Revenues to 2023 for the overall world market and main submarkets - you discover that industry's prospects
• Forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see regional and national sales predictions
• Discussions and profiles of leading companies - you find products, services, capabilities, developments and outlooks
• Interviews with authorities in the industry - you discover debates and opinions to help you stay ahead
• Understanding of competition and opportunities - you see what affects that industry, learning what shapes its future
• Analysis of what stimulates and restrains the market - you assess challenges and strengths, helping you compete and gain advantages
• Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for insight.

Our knowledge costs only a tiny fraction of potential profits from your understanding and harnessing that market. See its growth potential and find what you can gain.

Ordering now lets you discover predictions to 2023, finding information you need

Visiongain's investigation is for everyone needing analysis of drug development technologies. You find data, trends and potentials. Please order our report now.

Contents

1. EXECUTIVE SUMMARY

1.1 Cell-Based Assays: World Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report

2. AN INTRODUCTION TO CELL-BASED ASSAYS

2.1 Drug Discovery and Development
  2.1.1 Approaches to Drug Development
2.2 Drug Screening Assays
  2.2.1 Animal Models
  2.2.2 Biochemical Assays
  2.2.3 Applications for Biochemical Assays
    2.2.3.1 Lead Identification
    2.2.3.2 Toxicity Testing
2.3 Cell-Based Assays
  2.3.1 Assay Format
  2.3.2 Assay Detection Technology
  2.3.3 Cells Used in a Cell-Based Assay
    2.3.3.1 Immortalised Cell Lines
    2.3.3.2 Primary Cells
    2.3.3.3 Stem Cells
  2.3.4 Uses for Cell-Based Assays in Drug Discovery and Development
    2.3.4.1 Target Validation
    2.3.4.2 Primary Screening
    2.3.4.3 Secondary Screening
    2.3.4.4 ADME Screening
    2.3.4.5 High Throughput Screening

3. THE CELL-BASED ASSAYS MARKET 2013-2023

3.1 The Cell-Based Assays Market 2011-2012
3.2 The Cell-Based Assays Market Forecast, 2013-2023
3.3 Cell-Based Assay Services Submarket (Outsourcing), 2012-2023
  3.3.1 Outsourced Cell-Based Assay Services Submarket: Revenue Forecast 2012-2023
3.4 Cell-Based Assay Products Submarket, 2011
  3.4.1 Cell-Based Assay Products Submarket: Revenue Forecast 2012-2023
  3.4.2 Cell-Based Assay Product Categories
    3.4.2.1 Equipment
    3.4.2.2 Disposables
    3.4.2.3 Consumables
3.5 The Cell-Based Assays Market by Application
3.6 The Cell-Based Assays Market as a Share of R&D Spending

4. LEADING NATIONAL CELL-BASED ASSAY MARKETS 2012-2023

4.1 Leading National Markets for Cell-Based Assays 2011
4.2 Leading National Markets: Revenue Forecasts 2012-2023
4.3 The US: Revenues 2012-2023
4.4 Japan: Revenues 2012-2023
4.5 Europe
  4.5.1 The European Market: Revenues, 2011
  4.5.2 The European Market: Revenue Forecasts 2012-2023
4.6 Cell-Based Assays in the Leading Emerging Countries
  4.6.1 China: Revenues 2012-2023
  4.6.2 India: Revenues 2012-2023
  4.6.3 Russia: Revenues 2012-2023
  4.6.4 Brazil: Revenues 2012-2023

5. LEADING COMPANIES IN THE CELL-BASED ASSAYS MARKET

5.1 Cell-Based Assay Service Companies
  5.1.1 Global CROs
    5.1.1.1 Covance
    5.1.1.2 Pharmaceutical Product Development (PPD)
    5.1.1.3 Charles River Laboratories
  5.1.2 Specialist CROs and Service Companies
    5.1.2.1 Fluofarma
    5.1.2.2 Marin Biologic Laboratories
    5.1.2.3 MD Biosciences
5.2 Cell-Based Assay Product Suppliers
5.3 BD Biosciences
  5.3.1 BD Acquires Accuri Cytometers
5.4 Beckman Coulter
5.5 DiscoveRx
  5.5.1 DiscoveRx and GPCRs
5.6 EMD Millipore
  5.6.1 Expanding in Toxicity Research
5.7 Evotec
5.8 GE Healthcare
  5.8.1 GE Healthcare and Stem Cells
5.9 Life Technologies (Invitrogen)
5.10 Molecular Devices
5.11 PerkinElmer
  5.11.1 High Content Screening
  5.11.2 Caliper Life Sciences
    5.11.2.1 Caliper Discovery Alliances and Services
5.12 Promega
  5.12.1 Multiplexing Toxicity Testing Tools
  5.12.2 Stem Cells
5.13 Sigma-Aldrich
  5.13.1 Sigma's ADME-Tox Services
5.14 Thermo Fisher Scientific
5.15 TTP LabTech
  5.15.1 Chemotaxis Research

6. CELL-BASED ASSAYS: INDUSTRY TRENDS 2013-2023

6.1 Strengths and Weaknesses of the Cell-Based Assays Market
  6.1.1 Cell-Based Assays are More Biologically Relevant
  6.1.2 Two-Dimensional Cell Assays Have Limitations
  6.1.3 An Alternative to Animal Testing
6.2 Opportunities and Threats in the Cell-Based Assays Market 2013-2023
  6.2.1 Social Developments
  6.2.2 Technological Advances
  6.2.3 Economic Pressures
  6.2.4 Political Issues
6.3 Stem Cells
  6.3.1 The Need for Stem Cells in Cell-Based Assays
  6.3.2 Stem Cells Hold Significant Potential
  6.3.3 Induced Pluripotent Stem Cells: An Uncontroversial and Abundant Source
  6.3.4 Companies Providing Stem Cell Products for the Cell-Based Assay Market
    6.3.4.1 Axiogenesis
    6.3.4.2 Cellular Dynamics International
    6.3.4.3 MultiCell Technologies
    6.3.4.4 Stem Cell Innovations
6.4 G-Protein-Coupled Receptors (GPCRs): A Common Drug Discovery Target
  6.4.1 The Role of Cell-Based Assays
  6.4.2 Allosteric GPCRs Provide a New Approach
6.5 Miniaturisation and Automation
  6.5.1 The Demand for Miniaturisation
  6.5.2 Microfluidics
    6.5.2.1 The Future Potential of Microfluidics
  6.5.3 The Trend Towards Automation
  6.5.4 Multiplexing: Making Cell-Based Assays More Efficient
6.6 Detection in Cell-Based Assays
  6.6.1 High Content Screening (HCS)
    6.6.1.1 Future Developments in HCS
  6.6.2 Label-Free Technology
    6.6.2.1 The Potential of Label-Free Assays
    6.6.2.2 CellKey (Molecular Devices)
    6.6.2.3 Epic (Corning)
    6.6.2.4 xCELLigence (Roche Applied Science/ACEA Biosciences)
6.7 Three-Dimensional Cell-Based Assays: Closer to the True Cellular Environment
  6.7.1 Challenges in 3D Cell Culture
6.8 Toxicity Testing: A Key Market for Cell-Based Assays
  6.8.1 Alternative Approaches
  6.8.2 Restraints on Development
  6.8.3 Apredica
6.9 Outsourcing Cell-Based Assays
  6.9.1 Why Outsource?
6.10 Growing Interest in Biologics and Biosimilars: A Trend in the Pharmaceutical Industry

7. RESEARCH INTERVIEWS

7.1 Spokesperson from EMD Millipore
  7.1.1 EMD Millipore
  7.1.2 The Current Cell-Based Assay Market
  7.1.3 Market Pipeline
  7.1.4 Unique Challenges in the Market
  7.1.5 Future Perspectives
7.2 Dr. Jan Ehlert, ProQinase
  7.2.1 ProQinase
  7.2.2 Challenge Facing Cell-Based Assay Use
  7.2.3 The Cell-Based Assay Market Environment
  7.2.4 Future Perspectives
7.3 Spokesperson from Evotec
  7.3.1 Evotec
  7.3.2 Cell-Based Assays: Advantages & Disadvantages
  7.3.3 Competition in the Marketplace
  7.3.4 Future Directions

8. CONCLUSIONS FROM OUR STUDY

8.1 The Cell-Based Assays Market in 2011
8.2 Outlook for the Cell-Based Assays Market 2012-2023
  8.2.1 Regional Outlook for the Market 2012-2023
8.3 Future Opportunities for Cell-Based Assay Developers
8.4 Challenges to be Overcome

List Of Tables

LIST OF TABLES

Table 2.1 Key Parameters Required in Drug Discovery and Development
Table 2.2 Selected Label-Free Detection Technologies Used for Cell-Based Assays
Table 3.1 Cell-Based Assays Market by Sector, 2010 & 2011
Table 3.2 Cell-Based Assays Market: Overall World Market and Submarket Revenues, 2011-2023
Table 3.3 Cell-Based Assays Market: Drivers and Restraints, 2012-2023
Table 3.4 Drug Discovery Outsourcing: Drivers, 2013
Table 3.5 Cell-Based Assay Services Submarket: Revenue Forecast 2012-2023
Table 3.6 Cell-Based Assays: Submarket Shares, 2011-2023
Table 3.7 Cell-Based Assay Products Submarket: Revenue Forecast, 2012-2023
Table 3.8 Commercially-Available Robotic Systems for Liquid Handling and Cell Culture
Table 3.9 Cell-Based Assays Market by Application, 2011
Table 3.10 Pharmaceutical R&D: Global Spending Forecast, 2012-2023
Table 3.11 Pharmaceutical R&D Spending by Developmental Stage, 2011
Table 4.1 Cell-Based Assays Market by Region, 2011
Table 4.2 Developed Cell-Based Assays Markets: Drivers and Restraints, 2012-2023
Table 4.3 Emerging Cell-Based Assays Markets: Drivers and Restraints, 2012-2023
Table 4.4 Cell-Based Assays Market: Revenue Forecasts by Region, 2012-2023
Table 4.5 Cell-Based Assays Market: Seven Major Markets versus the Rest of the World, 2011, 2017 & 2023
Table 4.6 US Cell-Based Assays Market: Revenue Forecast, 2012-2023
Table 4.7 Japanese Cell-Based Assays Market: Revenue Forecast, 2012-2023
Table 4.8 European Cell-Based Assays Market by Leading Country, 2011
Table 4.9 European Cell-Based Assays Market: Revenue Forecasts for Leading Countries, 2012-2017
Table 4.10 European Cell-Based Assays Market: Revenue Forecasts for Leading Countries, 2017-2023
Table 4.11 Chinese Cell-Based Assays Market: Revenue Forecast, 2012-2023
Table 4.12 Indian Cell-Based Assays Market: Revenue Forecast, 2012-2023
Table 4.13 Russian Cell-Based Assays Market: Revenue Forecast, 2012-2023
Table 4.14 Brazilian Cell-Based Assays Market: Revenue Forecast, 2012-2023
Table 5.1 Covance: Revenue by Sector, 2009-2011
Table 5.2 Charles River Laboratories: Quarterly Net Sales by Sector, 2011
Table 5.3 Danaher: Revenues by Sector, 2011
Table 5.4 Merck KGaA: Revenues by Sector, 2011
Table 5.5 Evotec: Selected Discovery and Development Alliances, 2009-2011
Table 5.6 Life Technologies: Revenues by Sector, 2010-2011
Table 5.7 Life Technologies: Cell-Based Technology Platforms, 2011
Table 5.8 Danaher: Life Science Subsidiaries, 2011
Table 5.9 Perkin Elmer: Revenue ($bn) by Business, 2009-2011
Table 5.10 Sigma Aldrich: Revenue ($m) by Business, 2011
Table 5.11 Thermo Fisher: Revenue ($bn) by Business, 2011
Table 5.12 Thermo Fisher: Revenue ($bn) by Business, 2009-2011
Table 5.13 TTP LabTech: Selected Cell-Based Assay Relevant Products, 2011
Table 6.1 Cell-Based Assays Market: Strength and Weaknesses, 2013
Table 6.2 Cell-Based Assays Market: Opportunities and Threats, 2013-2023
Table 6.3 Pharmaceutical Outsourcing Market by Sector, 2011-2012
Table 6.4 Selected Companies Offering Stem Cell Products for Drug Development
Table 6.5 Reporter Gene Technology for Cell-Based Assays: Benefits and Weaknesses, 2013
Table 6.6 Selected Companies Offering Label-Free Assay Systems
Table 6.7 World Biologics Market: Revenues 2011 & 2016
Table 8.1 Cell-Based Assays Market: Overall Revenue Forecast and Submarket Shares, 2011-2023
Table 8.2 Cell-Based Assays Market: Overall Revenue Forecast and Regional Market Shares, 2011-2023

About

Russia: Revenues 2012-2023

The Russian cell based assays market was valued at $.08bn in 2011. The pharmaceutical market in Russia is well developed and remains one of the most dynamic sectors of the Russian economy. Currently the market is dominated by foreign producers, with many western drug manufacturers represented in the country. In fact, Russia currently imports about 80% of its pharmaceuticals, with domestically produced drugs often made from active ingredients obtained abroad (less than 1% of novel drugs sold in the country are produced in Russia).

However, this trend may begin to change as in 2010, it was announced that the Russian commercial drug industry is to receive a $163m investment – partly bankrolled by a state-owned non-profit corporation – to fund the development of up to 15 potential drug molecules that have unique mechanisms of action, taking them from the preclinical development stage through to Phase 2 clinical trials.

Furthermore, in making steps towards establishing a more domestic biotech and pharmaceutical market that can compete with other EU nations, the government has announced plans to invest $4 billion into the pharmaceutical sector over the coming 10 years and to boost the amount of drugs produced domestically to 50% by the year 2020. With the development of these drug molecules, it is likely a number of screening assays will be employed to test their activity in target cells to measure possible cellular or biochemical effects.

It is for this reason visiongain predicts that in line with the financial investment in drug discovery, and the drive towards establishing a domestic market which is not so dependant on western imports, the market for cell based assays (and drug discovery in general) in Russia is expected to grow strongly during 2012-2023. Between 2011 and 2023, the Russia market will grow with a CAGR of 11.0%, reaching $0.28bn by the end of the forecast period.